Snovitra: Advanced Therapy for Erectile Dysfunction
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.59 | $35.26 (0%) | 🛒 Add to cart |
| 90 | $0.47 | $52.89 $42.14 (20%) | 🛒 Add to cart |
| 120 | $0.37 | $70.52 $44.72 (37%) | 🛒 Add to cart |
| 180 | $0.27 | $105.78 $48.16 (54%) | 🛒 Add to cart |
| 270 | $0.19 | $158.67 $51.60 (67%) | 🛒 Add to cart |
| 360 | $0.15
Best per pill | $211.56 $55.04 (74%) | 🛒 Add to cart |
| Product dosage: 40mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.85 | $50.74 (0%) | 🛒 Add to cart |
| 90 | $0.69 | $76.11 $61.92 (19%) | 🛒 Add to cart |
| 120 | $0.59 | $101.48 $71.38 (30%) | 🛒 Add to cart |
| 180 | $0.48 | $152.22 $86.86 (43%) | 🛒 Add to cart |
| 270 | $0.39 | $228.33 $106.64 (53%) | 🛒 Add to cart |
| 360 | $0.32
Best per pill | $304.44 $116.96 (62%) | 🛒 Add to cart |
Snovitra (vardenafil) is a prescription phosphodiesterase type 5 (PDE5) inhibitor specifically formulated for the treatment of erectile dysfunction. Developed with advanced pharmaceutical technology, it facilitates increased blood flow to the penile tissue upon sexual stimulation, enabling reliable and sustained erectile response. This medication is distinguished by its rapid onset of action and proven efficacy across a broad spectrum of patient demographics, including those with underlying conditions such as diabetes and hypertension. Snovitra represents a cornerstone in modern urological and sexual medicine, offering a clinically validated option for restoring sexual function and improving quality of life.
Features
- Active ingredient: Vardenafil hydrochloride
- Available in multiple dosages: 5mg, 10mg, 20mg
- Rapid onset of action, typically within 25-60 minutes
- Duration of efficacy up to 4-5 hours
- High selectivity for PDE5 enzyme inhibition
- Formulated for oral administration with or without food
- Manufactured under strict GMP (Good Manufacturing Practice) standards
Benefits
- Achieves and maintains erections sufficient for satisfactory sexual activity
- Enhances confidence and reduces performance-related anxiety
- Improves overall sexual satisfaction for both partners
- Supports treatment adherence due to predictable pharmacokinetic profile
- Offers flexibility in timing due to extended window of efficacy
- May contribute to improved emotional and relational well-being
Common use
Snovitra is primarily indicated for the management of erectile dysfunction (ED) in adult males. Erectile dysfunction is characterized by the consistent or recurrent inability to attain and/or maintain a penile erection sufficient for satisfactory sexual performance. The medication is utilized on an as-needed basis, taken prior to anticipated sexual activity. It is not an aphrodisiac and requires sexual stimulation to produce its therapeutic effect. Clinical use is supported by extensive research demonstrating significant improvement in International Index of Erectile Function (IIEF) scores among treated populations.
Dosage and direction
The recommended starting dose of Snovitra is 10mg, taken orally approximately 25-60 minutes before sexual activity. Based on efficacy and tolerability, the dose may be increased to a maximum of 20mg or decreased to 5mg. Dosage adjustment is particularly important for elderly patients, those with hepatic impairment, or those taking concomitant medications that may interact with vardenafil. The tablet should be swallowed whole with a glass of water; it may be taken with or without food, though high-fat meals may delay onset of action. The medication should not be taken more than once in a 24-hour period.
Precautions
Prior to initiating Snovitra therapy, a comprehensive medical evaluation should be conducted to assess cardiovascular status, as sexual activity carries potential cardiac risk. Patients with pre-existing cardiovascular conditions such as unstable angina, heart failure, or recent myocardial infarction should generally avoid use. Caution is advised in patients with anatomical penile deformity, predisposition to priapism, or bleeding disorders. Ophthalmological evaluation is recommended for patients with retinitis pigmentosa or other inherited retinal disorders. Avoid consumption of grapefruit or grapefruit juice during treatment, as it may increase plasma concentrations of vardenafil.
Contraindications
Snovitra is contraindicated in patients with known hypersensitivity to vardenafil or any component of the formulation. Concurrent administration with organic nitrates or nitric oxide donors in any form is absolutely contraindicated due to the risk of profound hypotension. Concomitant use with guanylate cyclase stimulators is also contraindicated. The medication is not indicated for use in women, children, or adolescents under 18 years of age. Patients with severe hepatic impairment should not use Snovitra.
Possible side effects
The most commonly reported adverse reactions include headache, flushing, rhinitis, dyspepsia, and dizziness. Less frequently reported effects include nasal congestion, back pain, myalgia, and nausea. Visual disturbances such as blurred vision, altered color perception, or photophobia may occur due to mild inhibition of PDE6. Priapism, though rare, constitutes a medical emergency requiring immediate attention. Sudden hearing loss or decrease has been reported in temporal association with PDE5 inhibitor use. Most adverse effects are mild to moderate in severity and transient in nature.
Drug interaction
Snovitra potentiates the hypotensive effects of nitrates and alpha-blockers, necessitating strict avoidance. Concomitant use with potent CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, or clarithromycin requires significant dose reduction. Moderate CYP3A4 inhibitors and CYP3A4 inducers may alter vardenafil concentrations. Caution is advised when co-administering with antihypertensive medications due to additive blood pressure-lowering effects. Interaction with other PDE5 inhibitors is not recommended.
Missed dose
As Snovitra is taken on an as-needed basis rather than on a fixed schedule, the concept of a “missed dose” does not apply in the conventional sense. If a dose is not taken within the planned timeframe before sexual activity, it may be taken later provided that the recommended minimum 24-hour interval between doses is maintained. Patients should not take additional tablets to make up for a missed timing opportunity.
Overdose
In cases of suspected overdose, standard supportive measures should be implemented. Expected manifestations would be an extension of the drug’s known pharmacological effects, including severe hypotension, syncope, and prolonged erection. Priapism requires immediate urological intervention to prevent permanent tissue damage. Hemodialysis is not expected to significantly enhance elimination due to high protein binding and extensive tissue distribution. Management should focus on maintaining cardiovascular stability and symptomatic treatment.
Storage
Store Snovitra tablets at room temperature (15-30°C or 59-86°F) in their original container, protected from light and moisture. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Properly discard any unused or expired medication through medication take-back programs or according to local regulations.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Snovitra is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual response to treatment may vary. Patients should discuss their medical history, current medications, and treatment options with their physician before initiating therapy. Never share prescription medications with others.
Reviews
Clinical studies demonstrate that Snovitra significantly improves erectile function across various patient populations. In a randomized, double-blind, placebo-controlled trial involving 805 men with erectile dysfunction, 85% of patients receiving vardenafil 20mg reported improved erections compared to 28% receiving placebo. Another study specifically examining diabetic patients with ED showed 72% of vardenafil-treated patients achieving successful intercourse attempts. Long-term extension studies indicate maintained efficacy and good tolerability profile over 2 years of treatment. Patient-reported outcomes consistently show improvements in confidence, relationship satisfaction, and overall quality of life measures.